Skip to content

Targovax to present at 5th Neoantigen Summit Europe in Amsterdam

Oslo, 26 April 2022 – Targovax ASA announces that members of its executive management team are invited for oral presentations and a panel discussion at the 5th Neoantigen Summit Europe in Amsterdam 27-28 April.

Presentation: Uncovering the Benefits of Personalized Vaccines in a Clinical Setting
Presenter: Dr. Erik Digman Wiklund (CEO)
Date: 27 April 2022
Time: 10:00 CET

Presentation: Clinical Combination Strategies with Oncolytic Vaccines in Solid Tumors
Presenter: Dr. Victor Levitsky (CSO)
Date: 28 April 2022
Time: 15:30 CET

Panel Discussion: Evaluating Combination Therapies to Maximize Anti-Tumour Immune Activity
Participants from Targovax: Erik Digman Wiklund (CEO), Victor Levitsky (CSO)
Date: 28 April 2022
Time: 16:00 CET

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536

Renate Birkeli, Investor Relations
Phone: +47 922 61 624

Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives. Targovax is assessing its product candidates in different cancer indications, including melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging clinical data in several indications, both as monotherapy and in immunotherapy and chemotherapy combinations, the next development step for ONCOS-102 will be to further improve immune activation and clinical response in melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and providing deep mechanistic insights, Targovax is expanding its ONCOS program into delivery of circular RNA and targeting KRAS mutant cancers with the aim of establishing a platform for development of a rich pipeline of innovative future immunotherapy product candidates.

Source: Targovax